ObesityPhase 3NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
A Phase 3 study testing Cagrisema and Semaglutide in people with Obesity and Type 2 Diabetes, run by Novo Nordisk A/S at 303 sites in 19 countries.
Trial summary
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity, Type 2 Diabetes
- What is being tested?
- Cagrisema and Semaglutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,500 participants
- Where
- 303 sitesin 19 countries
- Study dates
- 21 May 2026to 19 Apr 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 years or above at the time of signing the informed consent.
- BMI≥ 35.0 kg/m^2.
- Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.
Who cannot join
- A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records.
- Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.
Trial locations and contacts
303 sites in 19 countries. Contact the study team or a site near you to ask about taking part.
303 sites in 19 countries
United States99 sites, 5 recruiting
- Active, not recruiting
Amarillo Med Spec LLP
Amarillo, Texas, 79124
- Completed
University of Colorado Hospital
Aurora, Colorado, 80045
- Active, not recruiting
Texas Diab & Endo, P.A.
Austin, Texas, 78731
- Active, not recruiting
Velocity Clinical Research Austin
Austin, Texas, 78759
- Not yet recruiting
Heritage Valley Medical Group
Beaver, Pennsylvania, 15009
- Active, not recruiting
Belzoni Clinical Research
Belzoni, Mississippi, 39038
- Active, not recruiting
Uni of Alabama at Birmingham
Birmingham, Alabama, 35294
- Active, not recruiting
Northern Pines Hlth Ctr, PC
Buckley, Michigan, 49620
- Active, not recruiting
Clinical Research Professionals
Chesterfield, Missouri, 63005
- Active, not recruiting
Cedar-Crosse Research Center
Chicago, Illinois, 60607
- Active, not recruiting
TBMR & Alcanza
Clearwater, Florida, 33761
- Active, not recruiting
Hope Clin Res & Wellness
Conyers, Georgia, 30094
- Active, not recruiting
Clinical Res Collaborative
Cumberland, Rhode Island, 02864
- Active, not recruiting
Velocity Clin Res, Dallas
Dallas, Texas, 75230
- Active, not recruiting
North Texas Endocrine Center
Dallas, Texas, 75231
- Active, not recruiting
Headlands Research California, LLC
Escondido, California, 92025
- Active, not recruiting
Neighborhood Healthcare
Escondido, California, 92025
- Active, not recruiting
Cedar Health Research
Euless, Texas, 76040
- Active, not recruiting
Lillestol Research LLC
Fargo, North Dakota, 58104
- Not yet recruiting
Plains Clinical Research Center, LLC
Fargo, North Dakota, 58104
- Active, not recruiting
Northeast Research Institute
Fleming Island, Florida, 32003
- Active, not recruiting
Velocity Clinical Research-Gaffney
Gaffney, South Carolina, 29340
- Active, not recruiting
Center for Adv Res & Education
Gainesville, Georgia, 30501
- Active, not recruiting
Elligo Health Research Inc
Gilbert, Arizona, 85296
- Active, not recruiting
Macoupin Fam Practice Ctr, LLP
Gillespie, Illinois, 62033
- Not yet recruiting
Prevea Health
Green Bay, Wisconsin, 54303
- Active, not recruiting
PharmQuest Life Sciences LLC
Greensboro, North Carolina, 27408
- Active, not recruiting
Physician's East Endocrinology
Greenville, North Carolina, 27834
- Active, not recruiting
Clinical Investigation Spec Gurnee
Gurnee, Illinois, 60031
- Active, not recruiting
Hatboro Med Associates
Hatboro, Pennsylvania, 19040
- Active, not recruiting
JCCT- Juno NW Houston
Houston, Texas, 77040
- Active, not recruiting
The Endocrine Center
Houston, Texas, 77079
- Active, not recruiting
Jackson Clinic
Jackson, Tennessee, 38305
- Active, not recruiting
Northeast Research Institute
Jacksonville, Florida, 32204
- Active, not recruiting
Westside Center For Clinical Research
Jacksonville, Florida, 32205
- Active, not recruiting
Medical Colleagues-Texas LLP
Katy, Texas, 77450
- Active, not recruiting
Sante Clinical Research
Kerrville, Texas, 78028
- Active, not recruiting
Holston Medical Group
Kingsport, Tennessee, 37660
- Active, not recruiting
Diabetes & Endocrine Specialists - La Mesa
La Mesa, California, 91942
- Active, not recruiting
Radiance Clinical Research
Lampasas, Texas, 76550
- Active, not recruiting
Aeres Clinical Research
Laredo, Texas, 78041
- Active, not recruiting
The Research Group of Lexington LLC
Lexington, Kentucky, 40503
- Active, not recruiting
Clinical Trials Research_Sacramento
Lincoln, California, 95648
- Active, not recruiting
Arkansas Clinical Research
Little Rock, Arkansas, 72205
- Active, not recruiting
Woodland Int. Research Group
Little Rock, Arkansas, 72211
- Active, not recruiting
Loma Linda University Faculty Medical Clinics
Loma Linda, California, 92354
- Active, not recruiting
DCOL Ctr for Clin Res
Longview, Texas, 75605
- Active, not recruiting
Pacific Clinical Studies
Los Alamitos, California, 90720
- Active, not recruiting
Advanced Medical Research
Maumee, Ohio, 43537
- Active, not recruiting
RGV Endocrine Center
McAllen, Texas, 78503
- Active, not recruiting
CNS Healthcare
Memphis, Tennessee, 38119
- Active, not recruiting
Solaris Clinical Research
Meridian, Idaho, 83646
- Active, not recruiting
Bioclinical Research Alliance
Miami, Florida, 33155
- Active, not recruiting
New Horizon Research Center
Miami, Florida, 33165
- Not yet recruiting
International Diabetes Center
Minneapolis, Minnesota, 55416
- Active, not recruiting
South Broward Research LLC
Miramar, Florida, 33027
- Active, not recruiting
Carteret Medical Group
Morehead City, North Carolina, 28557
- Active, not recruiting
Centricity Rsrch MHCity Multi
Morehead City, North Carolina, 28557
- Active, not recruiting
HealthStar Physicians, PC
Morristown, Tennessee, 37813
- Active, not recruiting
Clinical Research Associates
Nashville, Tennessee, 37203
- Active, not recruiting
Health Res of Hampton Roads
Newport News, Virginia, 23606
- Active, not recruiting
Tidewater Physicians Multispecialty Group
Newport News, Virginia, 23606
- Active, not recruiting
Alliance for Multispecialty Research
Newton, Kansas, 67114
- Active, not recruiting
Alliance for Multispecialty Research
Norman, Oklahoma, 73069
- Active, not recruiting
Lynn Institute of Norman
Norman, Oklahoma, 73072
- Active, not recruiting
Valley Clinical Trials
Northridge, California, 91325
- Active, not recruiting
West Orange Endocrinology
Ocoee, Florida, 34761
- Active, not recruiting
Oviedo Medical Research, LLC
Oviedo, Florida, 32765
- Active, not recruiting
Desert Oasis Healthcare
Palm Springs, California, 92262
- Active, not recruiting
Cahaba Research
Pelham, Alabama, 35124
- Active, not recruiting
Clinical Trial Services Corp
Pembroke Pines, Florida, 33024
- Active, not recruiting
Northeast Endocrine Metabolic Associates
Philadelphia, Pennsylvania, 19114
- Active, not recruiting
Velocity Clinical Research-Phoenix
Phoenix, Arizona, 85006
- Active, not recruiting
AES Minneapolis DRS
Richfield, Minnesota, 55423
- Active, not recruiting
National Clin Res Inc.
Richmond, Virginia, 23294
- Not yet recruiting
Endo and Metabolic Consultants
Rockville, Maryland, 20852
- Active, not recruiting
Endocrine Research Solutions, Inc
Roswell, Georgia, 30076
- Active, not recruiting
J.Lewis Research Inc
Salt Lake City, Utah, 84109
- Active, not recruiting
J.Lewis Research Inc
Salt Lake City, Utah, 84121
- Active, not recruiting
Quality Research Inc
San Antonio, Texas, 78209
- Active, not recruiting
AES San Antonio
San Antonio, Texas, 78229
- Active, not recruiting
Northeast Clinical Research of San Antonio
San Antonio, Texas, 78233
- Active, not recruiting
Linda Vista Health Care Ctr
San Diego, California, 92111
- Active, not recruiting
Diabetes & Endo Tx Specialists
Sandy City, Utah, 84093
- Active, not recruiting
Consano Clinical Research, LLC
Shavano Park, Texas, 78231
- Active, not recruiting
Endeavor Health
Skokie, Illinois, 60077
- Active, not recruiting
Evanston Premier Hlthcr Res
Skokie, Illinois, 60077
- Active, not recruiting
J.Lewis Research Inc
South Jordan, Utah, 84095
- Active, not recruiting
Spartanburg Medical Research
Spartanburg, South Carolina, 29303
- Active, not recruiting
Amicis Centers of Clinical Research
St Louis, Missouri, 63128
- Active, not recruiting
Piedmont Healthcare/Research
Statesville, North Carolina, 28625
- Active, not recruiting
Mt Olympus Medical Research, LLC
Sugar Land, Texas, 77478
- Active, not recruiting
Cotton O'Neil Diab & Endo Ctr
Topeka, Kansas, 66606
- Active, not recruiting
Velocity Clin Res - Van Nuys
Van Nuys, California, 91405
- Active, not recruiting
Flourish Research - CA
Walnut Creek, California, 94598
- Active, not recruiting
Iowa Diabetes Research
West Des Moines, Iowa, 50266
- Active, not recruiting
Southgate Medical Group, LLP
West Seneca, New York, 14224
- Active, not recruiting
Accellacare Wilmington
Wilmington, North Carolina, 28401
- Active, not recruiting
North Georgia Clinical Research
Woodstock, Georgia, 30189-4255
Canada21 sites, 1 recruiting
- Active, not recruiting
Centricity Research Brampton Endocrinology
Brampton, Ontario, L6S 0C6
- Active, not recruiting
C-Health Partners
Calgary, Alberta, T2V 4J2
- Not yet recruiting
Apex Trials
Guelph, Ontario, N1G 0B4
- Active, not recruiting
Nova Scotia Hlth Halifax
Halifax, Nova Scotia, B3H1V7
- Active, not recruiting
Hamilton Medical Research Group
Hamilton, Ontario, L8L 5G4
- Active, not recruiting
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8L 5G4
- Active, not recruiting
Wharton Medical Clinic Clinical Trials (Hamilton)
Hamilton, Ontario, L8L 5G8
- Active, not recruiting
Kelowna Health and Memory Centre Ltd.
Kelowna, British Columbia, V1Y 5A8
- Active, not recruiting
Medical Arts Health Research Group_Kelowna
Kelowna, British Columbia, V1Y4N7
- Active, not recruiting
Milestone Research
London, Ontario, N5W 6A2
- Active, not recruiting
G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7
- Active, not recruiting
Centre Medical Acadie
Montreal, Quebec, H4N 2W2
- Active, not recruiting
Centricity Res Pointe-Claire
Pointe-Claire, Quebec, H9R 4S3
- Active, not recruiting
Diex Recherche Quebec
Québec, G1V 4T3
- Active, not recruiting
Alpha Recherche Clinique - Lebourgneuf
Québec, G2J 0C4
- Active, not recruiting
Bluewater Clin Res Group Inc
Sarnia, Ontario, N7T 4X3
- Active, not recruiting
Ocean West Research Clinic
Surrey, British Columbia, V3Z 2N6
- Active, not recruiting
Hilltop Medical Clinic
Surrey, British Columbia, V4A 0C1
- Active, not recruiting
Care Access Cape Breton
Sydney, Nova Scotia, B1M 0A1
- Active, not recruiting
Diabetes Heart Research Centre
Toronto, Ontario, M6G 1M2
- Active, not recruiting
Dr. M.B. Jones Inc
Victoria, British Columbia, V8V 4A1
Argentina15 sites, 1 recruiting
- Active, not recruiting
OMI- Organización Médica de Investigación
Buenos Aires, C1015
- Active, not recruiting
Kynet Recoleta
Buenos Aires, C1119ACU
- Active, not recruiting
Hospital Sirio Libanes
Buenos Aires, C1419
- Active, not recruiting
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
Buenos Aires, C1425AGC
- Active, not recruiting
CEMEDIC
CABA, Buenos Aires, C1440CFD
- Not yet recruiting
CEDIC Centro de Investigación Clínica
CABA, C1060ABA
- Active, not recruiting
CIPREC Arenales
CABA, C1061AAS.
- Active, not recruiting
Centro Médico Viamonte SRL
CABA, C1120AAC
- Active, not recruiting
Centro de Investigaciones Metabólicas
Capital Federal, Buenos Aires, C1056ABI
- Active, not recruiting
CICEMO- Consultorio (Av Directorio)
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1424CIQ
- Active, not recruiting
Centro Médico Arsema
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1427
- Active, not recruiting
Instituto Centenario
Ciudad de Buenos Aires, C1204AAD
- Active, not recruiting
Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de Julio
San Miguel de Tucumán, Tucumán Province, T4000DPX
- Active, not recruiting
CEDIR - Centro de diagnóstico y rehabilitación Santa Fe
Santa Fe, S3000FSO
- Active, not recruiting
Sanatorio Norte
Santiago del Estero, G4200
Poland15 sites, 4 recruiting
- Active, not recruiting
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, 15-276
- Not yet recruiting
Gabinet Leczenia Otylosci i Chorob Dietozaleznych
Bialystok, 15-281
- Active, not recruiting
Kresmed Sp. z o. o.
Bialystok, 15-481
- Recruiting
Renew Clinic Sp. z o.o.
Bialystok, 15-797
- Active, not recruiting
Gierach-Med
Bydgoszcz, 85-796
- Active, not recruiting
ETG Lublin Sp. z o.o.
Dębica, 39-200
- Active, not recruiting
Pro Familia Altera Sp. z o.o.
Katowice, 40-648
- Active, not recruiting
Vita Longa Sp. z o. o.
Katowice, 40-748
- Active, not recruiting
Małopolskie Centrum Kliniczne
Krakow, 30-149
- Active, not recruiting
Maciej Wiza Gaja Poradnie Lekarskie
Poznan, 61-251
- Active, not recruiting
Centrum Medyczne Medyk Sp.zo.o. Sp.k.
Rzeszów, 35-055
- Active, not recruiting
Gyncentrum Sp. z o. o.
Warsaw, 00-124
- Active, not recruiting
Medon Clinical Research Sp. z o.o.
Warsaw, 02-679
- Not yet recruiting
Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego
Wroclaw, 51-149
- Not yet recruiting
Centrum Medyczne Oporow
Wroclaw, 52-416
South Africa15 sites
- Active, not recruiting
IATROS International
Bloemfontein, Free State, 9301
- Active, not recruiting
Medi-Clinic Bloemfontein
Bloemfontein, Free State, 9301
- Active, not recruiting
Tread Research (Pty)Ltd
Cape Town, Western Cape, 7500
- Active, not recruiting
Dr Pillay's Rooms
Durban, KwaZulu-Natal, 4450
- Active, not recruiting
Soweto Clinical Trial Centre
Johannesburg, Gauteng, 1818
- Active, not recruiting
Hemant Makan
Johannesburg, Gauteng, 1827
- Active, not recruiting
Newtown Clinical Research
Johannesburg, Gauteng, 2001
- Active, not recruiting
Wits Bara Clinical Trial Site
Johannesburg, Gauteng, 2013
- Active, not recruiting
Sandton Medical Research
Johannesburg, Gauteng, 2196
- Active, not recruiting
Lenasia Clinical Trial Centre
Lenasia, Gauteng, 1827
- Active, not recruiting
Dr Hendrik Snyman's Practice
Mossel Bay, Western Cape, 6500
- Active, not recruiting
Paarl Research Centre
Paarl, Cape Town, Western Cape, 7646
- Active, not recruiting
Phoenix Pharma
Port Elizabeth, Eastern Cape, 6001
- Active, not recruiting
Clinical Trial Systems (CTC)
Pretoria, Gauteng, 0186
- Active, not recruiting
Clinical Trials Network Helderberg (Pty) Ltd
Somerset West, Western Cape, 7130
Bulgaria14 sites
- Active, not recruiting
MC For Life EOOD
Burgas, 8000
- Active, not recruiting
MC Kazanlak EOOD
Kazanlak, 6100
- Active, not recruiting
Medical center Medi City 21 OOD
Kyustendil, 2500
- Active, not recruiting
OCSOMCE - Dr. Albena Dinkova EOOD
Pleven, 5800
- Completed
AIPSMCEMDID - Dr. Georgi Levterov EOOD
Plovdiv, 4000
- Active, not recruiting
DCC Sveti Georgi EOOD
Plovdiv, 4002
- Active, not recruiting
Hipocrat 9 - Dr. Rumyana Boykova - Draganova - AISPEMD EOOD
Sofia, 1463
- Active, not recruiting
DCC XX - Sofia EOOD, Endocrinology
Sofia, 1618
- Active, not recruiting
MC Diamedical - 2013 OOD, Sofia
Sofia, 1618
- Active, not recruiting
Medical Centre Medical Arts Medico-dental centre
Sofia, 1618
- Completed
DCC XXV Sofia EOOD, Endocrinology Consulting room
Sofia, 1712
- Active, not recruiting
UMHAT Prof. Dr. Stoyan Kirkovich AD
Stara Zagora, 6003
- Active, not recruiting
AIPSMC Dr. Evelina Zlatanova EOOD
Varna, 9010
- Completed
MC Nevromedics EOOD, Internal Diseases
Veliko Tarnovo, 5005
Hungary14 sites, 2 recruiting
- Active, not recruiting
Lausmed Kft.
Baja, Bács-Kiskun county, 6500
- Active, not recruiting
EURÉKA-CENTER Orvosi és Szolgáltató Betéti Társaság
Baja, 6500
- Active, not recruiting
Dr. Lakatos Ferenc Kardiológus ,Belgyógyász Magán szakrendelés
Békéscsaba, Bekes County, 5600
- Active, not recruiting
Békés Vármegyei Központi Kórház
Békéscsaba, 5600
- Active, not recruiting
Trial Pharma Kft.
Békéscsaba, 5600
- Active, not recruiting
Biatros Kft.
Biatorbágy, 2051
- Active, not recruiting
Óbudai Egészségügyi Centrum
Budapest, Pest County, 1036
- Not yet recruiting
Szatmári-Med Kft.
Budapest, Pest County, 1213
- Active, not recruiting
Semmelweis Egyetem
Budapest, 1083
- Active, not recruiting
Cardiogeneral Kft.
Budapest, H-1141
- Active, not recruiting
Medifarma-98 Kft.
Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400
- Active, not recruiting
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
Szeged, Csongrád-Csanád, 6725
- Not yet recruiting
Mentaház Kft.
Székesfehérvár, 8000
- Active, not recruiting
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet
Szolnok, 5000
Greece13 sites, 3 recruiting
- Not yet recruiting
University General Hospital Of Alexandroupoli - First Department of Internal Medicine
Alexandroupoli, 68100
- Active, not recruiting
Evangelismos S.A. - Endocrinology department
Athens, 10676
- Active, not recruiting
Laiko General Hospital Of Athens - 1st department of Internal Medicine
Athens, 115 27
- Active, not recruiting
Athens Medical Center S.A. (Iatriko Psychikou) - Department of Internal Medicine & Metabolic Diseases
Athens, 11525
- Active, not recruiting
General Hospital Of Athens Alexandra - Clinical Therapeutics
Athens, 11528
- Not yet recruiting
General Hospital Of Lamia - Internal Medicine Clinic
Lamia, 35100
- Active, not recruiting
Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit
Marousi, 15125
- Active, not recruiting
Athens Medical Center S.A. (Iatriko P. Falirou) - Diabetes and Clinical Research Center
Palaió Fáliro, 17562
- Active, not recruiting
Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department
Peristeri, 121 31
- Not yet recruiting
Athens Medical Center S.A., European Interbalkan Medical Center - Department of Internal Medicine
Thessaloniki, 546 39
- Active, not recruiting
General Hospital Of Thessaloniki G Gennimatas - Internal Medicine Clinic
Thessaloniki, 54635
- Active, not recruiting
NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes
Thessaloniki, 54635
- Active, not recruiting
Thermi Clinic S.A. - Diabetes and Internal Medicine Department
Thessaloniki, 57001
Spain13 sites, 4 recruiting
- Active, not recruiting
Complejo Hospitalario Universitario A Coruña
A Coruña, 15006
- Active, not recruiting
Hospital Comarcal de Antequera
Antequera, 29200
- Active, not recruiting
CAPSBE_CAP Ernest LLuch
Barcelona, 08028
- Not yet recruiting
Hospital Vall d'Hebron
Barcelona, 08035
- Active, not recruiting
Eap Osona Sud Alt Congost S.L.P
Centelles (Barcelona), 08540
- Active, not recruiting
Clínica Bofill
Girona, 17002
- Completed
Hosp. Univ. Ruber Juan Bravo_Endocrinología
Madrid, 28006
- Active, not recruiting
Hospital Universitario de la Princesa
Madrid, 28006
- Not yet recruiting
Hospital Universitario Sanitas Virgen del Mar
Madrid, 28016
- Not yet recruiting
Hospital Universitario de Fuenlabrada
Madrid, 28942
- Not yet recruiting
H. Clinico Univ. Virgen de la Victoria
Málaga, 29010
- Active, not recruiting
Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada
Manresa, 08243
- Active, not recruiting
Hosp. Recoletas Salud Campo Grande_Endoc y Nutric
Valladolid, 47004
Romania11 sites, 1 recruiting
- Active, not recruiting
CMI Dr Pop Lavinia
Baia Mare, Maramureş, 430222
- Not yet recruiting
Mariodiab Clinic SRL
Brasov, 500101
- Active, not recruiting
Sc Nicodiab Srl
Bucharest, 010507
- Active, not recruiting
Mat Cord Biomedica S.R.L.
Buzău, 120133
- Active, not recruiting
S.C. Top Diabet Srl
Craiova, Dolj, 200515
- Active, not recruiting
Grandmed SRL
Oradea, Bihor County, 410159
- Active, not recruiting
Spitalul Clinic Judetean De Urgenta Bihor
Oradea, 410469
- Active, not recruiting
Sc Sal Med Srl
Piteşti, 110424
- Active, not recruiting
Sc Mediab Srl
Târgu Mureş, Mureș County, 540142
- Active, not recruiting
Cabinet Medical Dr Geru SRL
Timișoara, 300288
- Active, not recruiting
Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
Timișoara, 300723
Czechia9 sites
- Active, not recruiting
Fakultní nemocnice U sv. Anny v Brně
Brno, 656 91
- Active, not recruiting
Centrum zdraví Dolní Břežany, a.s.
Dolní Břežany, 252 41
- Active, not recruiting
KARDIOLOGIE - LIBEREC s.r.o.
Liberec, 460 01
- Active, not recruiting
Interní a diabetologická ordinace s.r.o.
Náchod, 54701
- Active, not recruiting
DIALINE s.r.o.
Plzeň 3, 301 00
- Active, not recruiting
ENDOTRIAL s.r.o.
Prague, 10400
- Active, not recruiting
Milan Kvapil s.r.o.
Prague, 149 00
- Active, not recruiting
EUC Klinika Praha a.s.
Prague, 150 00
- Active, not recruiting
Fledip s.r.o.
Prague, 160 00
France9 sites, 5 recruiting
- Not yet recruiting
CHU ROUEN_HOPITAL DE BOIS GUILLAUME_Service de Nutrition
Bois-Guillaume, 76230
- Not yet recruiting
CENTRE HOSPITALIER DE COLMAR_Endocrinologie/Diabetologie/Centre Nutritionnel
Colmar, 68024
- Active, not recruiting
LES HOPITAUX DE CHARTRES_HOPITAL LOUIS PASTEUR_Service d'endocrinologie
Le Coudray, 28630
- Active, not recruiting
APHP - LA PITIE SALPETRIERE _ Service de Nutrition
Paris, 75013
- Not yet recruiting
HOPITAL EUROPEEN GEORGES POMPIDOU_Service de nutrition et diabétologie
Paris, 75015
- Not yet recruiting
CHU DE BORDEAUX-HOPITAL HAUT LEVEQUE_Service d'Endocrinologie, Diabétologie et Maladies Métaboliques
Pessac, 33600
- Not yet recruiting
HCL-HOPITAL LYON SUD_Service d'Endocrinologie-Diabète-Nutrition
Pierre-Bénite, 69310
- Completed
CHU NANTES - HOPITAL NORD LAENNEC_Service d'Endocrinologie-Diabétologie-Nutrition
Saint-Herblain, 44800
- Active, not recruiting
CENTRE DE RECHERCHE CLINIQUE PORTES DU SUD_Service d'Endocrinologie-Diabétologie-Maladies Métaboliques
Vénissieux, 69200
Italy9 sites, 5 recruiting
- Active, not recruiting
INRCA Ancona - UOC Clinica Medica e Geriatrica
Ancorna, The Marches, 60127
- Not yet recruiting
AOU IRCCS Policlinico di Sant'Orsola Malpighi - UOC Endocrinologia e Prevenzione e Cura del Diabete
Bologna, Emilia-Romagna, 40138
- Not yet recruiting
Spedali Civili Brescia - SSD Endocrinologia
Brescia, Lombardy, 25123
- Active, not recruiting
Azienda Ospedaliero-Universitaria Renato Dulbecco
Catanzaro, 88100
- Not yet recruiting
IRCCS Ospedale Policlinico San Martino - U.O.D. Dietetica e Nutrizione Clinica
Genoa, Liguria, 16132
- Active, not recruiting
D.A.I. Oncologico - U.O.C. di Chirurgia Generale ad indirizzo Oncologico
Messina, Sicily, 98124
- Active, not recruiting
Ospedale San Raffaele S.r.l. - Unità di Cardio-metabolismo e Trials Clinici
Milan, Lombardy, 20132
- Not yet recruiting
Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia
Perugia, Pg, 06129
- Not yet recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, 56126
Austria8 sites
- Active, not recruiting
Medical University of Graz
Graz, 8036
- Active, not recruiting
Ordination Winhofer-Stöckl
Mattersburg, 7210
- Active, not recruiting
Fließer-Görzer [Ordination]
Saint Stefan, 8511
- Active, not recruiting
Klinik Landstraße
Vienna, 1030
- Active, not recruiting
Universitätsklinikum AKH Wien
Vienna, 1090
- Active, not recruiting
Ordination Dr. Günter Sokol
Vienna, 1120
- Active, not recruiting
Klinik Hietzing 3. Med. Abt.
Vienna, 1130
- Active, not recruiting
Itariu [Ordination]
Vienna, 1180
Netherlands8 sites, 1 recruiting
- Active, not recruiting
Progress Clinical Research Den Bosch
's-Hertogenbosch, North Brabant, 5223 LA
- Completed
Rijnstate Ziekenhuis
Arnhem, 6815 AD
- Active, not recruiting
PreCare Trial & Recruitment
Born, Limburg, 6121 XK
- Not yet recruiting
Catharina Zkh Eindhoven - Interne geneeskunde
Eindhoven, 5623 EJ
- Completed
Spaarne Gasthuis Hoofddorp - Interne
Hoofddorp, 2134 TM
- Active, not recruiting
Bethesda Diabetes Research Center
Hoogeveen, 7909 AA
- Completed
Ikazia Ziekenhuis
Rotterdam, 3083 AN
- Active, not recruiting
Medisch Centrum Thomsonplein
The Hague, 2565 KV
Portugal8 sites
- Active, not recruiting
ULS Almada-Seixal E.P.E. - HGO_Serviço de Endocrinologia
Almada, 2805-267
- Active, not recruiting
ULS Do Oeste E.P.E. - Unidade Caldas da Rainha_CAMI - Unidade de Diabetes
Caldas da Rainha, 2500-176
- Active, not recruiting
ULS Do Baixo Mondego, E.P.E. - HDFF_Serviço Cardiologia
Figueira da Foz Municipality, 3094-001
- Active, not recruiting
Hospital da Luz Lisboa, S.A._Serviço de Medicina Interna
Lisbon, 1500-650
- Active, not recruiting
Ucardio Centro Clinico Unidade Cardiovascular
Riachos, Torres Novas, Riachos, 2350-325
- Active, not recruiting
ULS De Matosinhos, E.P.E - HPH_Serviço de Endocrinologia
Senhora Da Hora, Matosinhos, 4464-513
- Active, not recruiting
Hospital Trofa Saude Senhor do Bonfim S.A_Unidade de Ensaios Clínicos
Vila do Conde, 4480-565
- Active, not recruiting
Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia
Vila Nova de Gaia, 4400-346
Slovakia8 sites
- Active, not recruiting
DIA - CLARUS s.r.o.
Bojnice, 97201
- Active, not recruiting
KARDIO-SANUS, spol. s r.o.
Bratislava, 84108
- Active, not recruiting
MEDISPEKTRUM s.r.o.
Bratislava, 851 01
- Active, not recruiting
Diab - Int, s.r.o.
Bytča, 014 01
- Active, not recruiting
HUMAN-CARE, s.r.o.
Košice, 040 01
- Active, not recruiting
ENDOMED, s.r.o.
Košice, 04013
- Active, not recruiting
DIAMARTIN, s. r. o.
Martin, 036 01
- Active, not recruiting
LUDIA, s. r. o.
Spišská Nová Ves, 05201
Australia7 sites
- Active, not recruiting
University of Sunshine Coast - Vitality Village
Birtinya, Queensland, 4575
- Active, not recruiting
Emeritus Research Melbourne
Camberwell, Victoria, 3124
- Active, not recruiting
Sydney Clinical Trials
Campbelltown, New South Wales, 2560
- Active, not recruiting
Gosford Renal Research
Gosford, New South Wales, 2250
- Active, not recruiting
Sydney Cardiometabolic Centre
Liverpool, New South Wales, 2170
- Active, not recruiting
Hunter Diabetes Centre
Merewether, New South Wales, 2291
- Active, not recruiting
University of Sunshine Coast - South Brisbane
South Brisbane, Queensland, 4101
Belgium7 sites, 1 recruiting
- Active, not recruiting
Anima Research Center
Alken, 3570
- Not yet recruiting
Cliniques universitaires Saint-Luc
Brussels, 1200
- Active, not recruiting
KORMONT
Kluisbergen, 9690
- Active, not recruiting
CHU Tivoli
La Louvière, 7100
- Active, not recruiting
MECLINAS
Mechelen, 2800
- Active, not recruiting
AZ Delta - Roeselare
Roeselare, 8800
- Active, not recruiting
KORMONT
Zwalm, 9630
About this study
Official title: A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
- Conditions
- Obesity, Type 2 Diabetes
- Being tested
- Cagrisema, Semaglutide
- Medical subject headings
- Obesity, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CagrisemaDrug
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
SemaglutideDrug
Semaglutide will be administered subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| Cagrisema - dose level 1 | Experimental | Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks. Receives: Drug: Cagrisema |
| Cagrisema - dose level 2 | Active comparator | Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks. Receives: Drug: Cagrisema |
| Semaglutide | Active comparator | Participants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks. Receives: Drug: Semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Relative change in body weight
Measured as percentage (%).
Measured: From randomisation (week 0) to end of treatment (week 72)
Secondary outcomes (25)
Relative change in body weight
Measured as %.
Measured: From randomisation (week 0) to end of treatment (week 72)
Change in Body Mass Index (BMI)
Measured as kilograms per square metre (kg/m^2).
Measured: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve greater than or equal to (≥) 30% weight reduction
Measured as count of participants.
Measured: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve ≥25% weight reduction
Measured as count of participants.
Measured: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve greater ≥ 20% weight reduction
Measured as count of participants.
Measured: From randomisation (week 0) to end of treatment (week 72)
Change in waist circumference
Measured in centimetre (cm).
Measured: From randomisation (week 0) to end of treatment (week 72)
Mean change in body weight
Measured in kilograms (kg).
Measured: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve a BMI less than (<) 30 kg/m^2
Measured as count of participants.
Measured: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve BMI <27 kg/m^2
Measured as count of participants.
Measured: end of treatment (week 72)
Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2
Measured as count of participants.
Measured: At end of treatment (week 72)
Number of participants who achieve a waist-to-height ratio < 0.53
Measured as count of participants.
Measured: At end of treatment (week 72)
Ratio to baseline : Total cholesterol
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : High density lipoprotein (HDL) cholesterol
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Low density lipoprotein (LDL) cholesterol
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Triglycerides
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline: Free fatty acids
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Non-HDL cholesterol
Measured in terms of ratio.
Measured: From baseline (week 0) to end of treatment (week 72)
Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function
Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.
Measured: From randomisation (week 0) to end of treatment (week 72)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.
Measured: From randomisation (week 0) to end of treatment (week 72)
Change in glycated haemoglobin (HbA1c)
Measured in %-points.
Measured: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve HbA1c <6.5%
Measured as count of participants.
Measured: At end of treatment (week 72)
Number of participants who achieve normal HbA1c <5.7%
Measured as count of participants.
Measured: At end of treatment (week 72)
Number of treatment-emergent adverse events (TEAEs)
Measured in number of events.
Measured: From randomisation (week 0) to end of study (week 80)
Number of treatment-emergent serious adverse events (TESAEs)
Measured in number of events.
Measured: From randomisation (week 0) to end of study (week 80)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start21 May 2026
- Primary completion23 Feb 2028 (estimated)
- Study completion19 Apr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 2,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07564414
- Sponsor's protocol ID
- NN9838-7910
- Other IDs
- U1111-1323-0372, 2025-522488-14, 2025
- Status last verified
- Sep 2026
- First submitted
- 27 Apr 2026
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07564414
- Acronym / sponsor ID
- NN9838-7910
- Conditions
- Obesity, Type 2 Diabetes
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 21 May 2026 (actual)
- Primary completion
- 23 Feb 2028 (estimated)
- Study completion
- 19 Apr 2028 (estimated)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cagrisema - dose level 1 | Experimental | Drug: CagrisemaParticipants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks. |
| Cagrisema - dose level 2 | Active comparator | Drug: CagrisemaParticipants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks. |
| Semaglutide | Active comparator | Drug: SemaglutideParticipants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 years or above at the time of signing the informed consent.
- BMI≥ 35.0 kg/m^2.
- Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.
Key exclusion criteria (2 listed)
- A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records.
- Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CagrisemaCagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously. | Drug | Cagrisema - dose level 1, Cagrisema - dose level 2 |
| SemaglutideSemaglutide will be administered subcutaneously. | Drug | Semaglutide |
Primary outcome
Relative change in body weight
Time frame: From randomisation (week 0) to end of treatment (week 72)
Measured as percentage (%).
25 secondary outcomes
Relative change in body weight
Time frame: From randomisation (week 0) to end of treatment (week 72)
Change in Body Mass Index (BMI)
Time frame: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve greater than or equal to (≥) 30% weight reduction
Time frame: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve ≥25% weight reduction
Time frame: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve greater ≥ 20% weight reduction
Time frame: From randomisation (week 0) to end of treatment (week 72)
Change in waist circumference
Time frame: From randomisation (week 0) to end of treatment (week 72)
Mean change in body weight
Time frame: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve a BMI less than (<) 30 kg/m^2
Time frame: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve BMI <27 kg/m^2
Time frame: end of treatment (week 72)
Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2
Time frame: At end of treatment (week 72)
Number of participants who achieve a waist-to-height ratio < 0.53
Time frame: At end of treatment (week 72)
Ratio to baseline : Total cholesterol
Time frame: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : High density lipoprotein (HDL) cholesterol
Time frame: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Low density lipoprotein (LDL) cholesterol
Time frame: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol
Time frame: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Triglycerides
Time frame: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline: Free fatty acids
Time frame: From baseline (week 0) to end of treatment (week 72)
Ratio to baseline : Non-HDL cholesterol
Time frame: From baseline (week 0) to end of treatment (week 72)
Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function
Time frame: From randomisation (week 0) to end of treatment (week 72)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function
Time frame: From randomisation (week 0) to end of treatment (week 72)
Change in glycated haemoglobin (HbA1c)
Time frame: From randomisation (week 0) to end of treatment (week 72)
Number of participants who achieve HbA1c <6.5%
Time frame: At end of treatment (week 72)
Number of participants who achieve normal HbA1c <5.7%
Time frame: At end of treatment (week 72)
Number of treatment-emergent adverse events (TEAEs)
Time frame: From randomisation (week 0) to end of study (week 80)
Number of treatment-emergent serious adverse events (TESAEs)
Time frame: From randomisation (week 0) to end of study (week 80)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Obesity
RecruitingPhase 4
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Class I/II Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Overweight and Obesity
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
303 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Cagrisema and Semaglutide in people with Obesity and Type 2 Diabetes, run by Novo Nordisk A/S at 303 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 303 sites in United States, Canada, Argentina, Poland, South Africa and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Novo Nordisk ((+1) 866-867-7178, clinicaltrials@novonordisk.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relative change in body weight (time frame: From randomisation (week 0) to end of treatment (week 72)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.